U.S. License Holder:
Amgen
Date of License:
August-22-2008
Last Update:
February-09-2019
FDA-Approved Indications
NPLATE (romiplostim) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in:
Adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy;
Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.